Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 4/20 | 0.48 |
| ▸ | AKT2 | P31751 | 4/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19079075 | 1.00 | CETP (0.53) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL23000963 | 1.00 | CETP (0.53) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL14666330 | 1.00 | CETP (0.53) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL17188245 | 1.00 | CETP (0.53) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL14666253 | 0.92 | LGALS8 (0.56) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL17188247 | 0.92 | LGALS8 (0.56) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL14666207 | 0.91 | MAPK1 (0.46) | CETPAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL10782436 | 0.90 | CETP (0.53) | CETPMAPK1 | |
| SCHEMBL3015938 | 0.90 | CETP (0.53) | CETPMAPK1 | |
| SCHEMBL19874824 | 0.90 | CETP (0.53) | CETPMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021252290-A2 | COMPOSITIONS AND METHODS FOR TREATING NOVEL CORONAVIRUS SARS-COV-2-MEDIATED INFLAMMATORY CONDITIONS | GRI BIO, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | CETP 693/4885AKT1 2455/4885AKT2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.